P-15: A Study of Paraoxonase I Gene Polymorphisms with The Risk and Severity of Non-Small Cell Lung Cancer (NSCLC) in Turkish Patients (Pages: 46-46)

Fadhil A *, Mehmet T , Onur R , Asuman S ,


Objective: Paraoxonase 1 is a high-density lipoprotein (HDL)-associated enzyme that was thought to against lung cancer (LC) because it may has a role in protecting from oxidative stress in the lung and circulation. PON 1 has two genetic polymorphisms in coding region; L55M and Q192R. In the present study, distribution of PON 1 L55M and Q192R polymorphisms and the effect of these polymorphisms on the risk of non-small cell lung cancer (NSCLC), and on the clinical severity of NSCLC in 52 NSCLC patients and 60 control subjects were examined. Materials and Methods: A hospital-based case-control study were undertaken in Ankara University Hospital. PON 1 L55M 55 and Q192R 192 genotypes were determined by PCR, RFLP and agarose gel electrophoresis techniques. Results: The analysis showed genotype distributions and allele frequencies for PON 1 Q192R polymorphism were not significantly different between controls and NSCLC patient group (p>0.05), but in genotype and allele distribution of PON 1 L55M polymorphism, there was significantly difference among groups (p<0.05). Genotype distributions for both polymorphisms were not significantly different between subgroups of squamous cell carcinoma and adenocarcinoma type. There was a statistically significant difference of NSCLC risk in mutant carriers (MM & LM), especially for current smokers and heavy smokers. Moreover, mutant genotypes present significantly lower risk of developing cancer in stage IV for NSCLC. Conclusion: Our results suggest that both of PON1 polymorphisms appear to be common genetic traits that are associated with a decreased risk and severity for NSCLC. The effect is especially strong for heavy smokers